Pfizer
TOPIC
 / company

Pfizer

Pfizer
Pfizer
The latest news, analysis and opinion on Pfizer. In-depth analysis, industry insights and expert opinion.
Chairman / President
Albert Bourla
CEO / Managing Director
Albert Bourla
CFO / Finance Director
Dave Denton
Industry
Pharmaceuticals
Website
pfizer.com
Headquarters address
235 East 42nd Street, New York, NY 10017, United States
Stock Code
NYSE:PFE
Year founded
1849
LATEST China Science NEWS

Landmark in-air refuelling test extends China’s drone swarm delivery range to US

videocam
15
This image shows a drone-to-drone refuel test flight with two signalling bulbs being blocked. Photo: NPU

BeOne Medicines names R&D chief Wang Lai as co-president amid global expansion

BeOne’s manufacturing facility in Guangzhou. Photo: Handout

How China cracked US ‘super code’ that controls most power grids in the world

videocam
15
China’s Southern Regional Electricity Market, the world’s largest unified power market, has fully switched to the homegrown Tianquan solver, which is 14 per cent faster than US rivals. Photo: EPA-EFE

China’s heat pump tech, Tokyo clarifies Taiwan stance: SCMP’s 7 highlights

Excavators unload coal in Binzhou, in eastern China’s Shandong province. Photo: AFP

Chinese team builds optical chip AI that is 100 times faster than Nvidia’s A100

22
Researchers said the chips could make AI “more sustainable”. Photo: Shutterstock
MORE China Science NEWS
US drugmakers are increasingly looking to Chinese biotechs as an answer to the revenue gaps left by the looming ‘patent cliff’. Illustration by Henry Wong
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

Made in China 2025

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Made in China 2025

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

videocam
A worker checks the position of a feeding tray in a pharmaceutical manufacturing facility at the Hengrui Biomedical Industrial Park in Lianyungang in Jiangsu province, on December 13, 2021. Photo: Getty Images
Science

Have Chinese chemists cracked the code for cheaper medicine production?

The research team’s straightforward alternative to expensive, complex and dangerous production method hailed as ‘Nobel Prize level’.

videocam
18
US-China relations

Xi-Trump summit opens window of opportunity for US firms at China import expo

More US companies are expected at this year’s China International Import Expo, hoping to secure deals in wake of bilateral summit.

videocam
Advertisement
Advertisement
Advertisement
Hong Kong economy

Letters | How Hong Kong can help Chinese drug makers go global

Readers discuss opportunities from medical innovation, tech standards in Hong Kong, and how to stop people treating corals like inanimate objects.

A view of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone on April 24. Photo: Edmond So
Donald Trump

Trump says Pfizer will cut drug prices for tariff relief

The White House is also planning a direct-to-consumer website called TrumpRx for Americans to buy medication.

Singapore

Singapore’s drug makers may be shielded from US tariffs: Deputy PM Gan

The city state may pursue a ceiling on tariff rates similar to deals that Washington has with other countries, Deputy PM Gan Kim Yong adds.

Biomedicine: Companies

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

The Pfizer deal is not good news for Chinese firms developing weight-loss drugs with the aim of reducing injections, an analyst says. Photo: Shutterstock
Biomedicine: Companies

China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug

The licensing deal for the HRS-1893 innovative drug could fetch as much as US$1.01 billion in milestone payments.

The headquarters of Jiangsu Hengrui Pharmaceutical in Lianyungang Economic and Technological Development Zone, in Jiangsu province. Photo: Costfoto/Future Publishing via Getty Images
Made in China 2025

China vows stronger biotech support as deals with global drug makers surge

Chinese developers signed one-third of all agreements with global drug firms in the first half of 2025.

Biomedicine: Companies

Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity investment in 3SBio.

European Union

EU chief Ursula von der Leyen easily survives parliament no-confidence vote

EU lawmakers dismissed allegations against Ursula von der Leyen regarding private text messaging with Pfizer’s CEO, misuse of funds, and election interference.

European Commission President Ursula von der Leyen survived a no-confidence vote amid far-right tensions and corruption allegations. Photo: EPA
Singapore

Singapore prioritising pharmaceutical supply chains in US tariff talks

Pharmaceutical supply chains account for more than 10 per cent of Singapore’s exports to the US.

Photo: Shutterstock
CSPC Pharmaceutical

Chinese biotech’s mega drug-licensing deals with multinationals surge

Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.

Biomedicine: Companies

Chinese biotech firm secures Pfizer deal despite trade tensions

Pfizer will produce the drug, which targets lung and colorectal cancers, in the US and take a US$100 million stake in China’s 3SBio.

videocam
Advertisement
Advertisement
Advertisement
European Union

EU’s von der Leyen loses court case over secret Pfizer texts

Wednesday’s ruling is likely to affect how the EU’s executive arm treats text messages in the future.

The New York Times had asked the court to force the disclosure of a message exchange between European Commission President Ursula von der Leyen and Pfizer’s CEO that could show how a costly vaccine deal was struck in 2021. Photo: via AP
Biomedicine: Companies

Hong Kong residents reticent to get latest Covid-19 jab, Moderna survey finds

About 52 per cent of Hong Kong respondents said they were willing to get the updated vaccine, compared with 58 per cent in Singapore.

Hong Kong healthcare and hospitals

Elderly Hongkongers can apply for Covid XBB variant vaccine starting Wednesday

Elderly residents can go to community vaccination stations run by private clinics or designated general outpatient clinics under Hospital Authority.

Hong Kong healthcare and hospitals

Hong Kong receives first batch of Covid XBB variant vaccines

Vaccination arrangements for the 100,000-jab batch manufactured by US drug firm Pfizer expected to be announced in December.

5
The first batch of Covid XBB variant vaccines has arrived in Hong Kong. Photo: Sam Tsang
Hong Kong healthcare and hospitals

Hong Kong’s private healthcare sector expected to offer RSV vaccine in December

British pharmaceutical company GSK beats Pfizer in race to offer vaccine that can protect elderly against common respiratory infection.

RSV can cause infections in the airways, lungs and middle ear, with young children and the elderly more likely to develop serious conditions. Photo: Shutterstock Images
Coronavirus US

Coronavirus: US FDA approves updated Covid-19 vaccines

The FDA decision opens the newest vaccines from Moderna and Pfizer and its partner BioNTech to most Americans even if they have never had a Covid vaccination.

Singapore

She died 4 days after a Covid booster jab. Singapore paid her family US$169,000

Filipino Ontal Charlene Vargas died of myocarditis, or inflammation of the heart. A coroner ruled it was likely related to the vaccine she had received.

6
Coronavirus China

China gives green light to 2 home-grown Covid-19 antiviral treatments

The approval comes during reprieve from tsunami of infections but another wave could be on the way after Lunar New Year migration.

The Covid-19 medication VV116 is one of two Chinese oral pill treatments approved for use in China on Sunday. Photo: Handout
Science

Chinese drug matches Paxlovid in treating less severe Covid symptoms

Patients who took the Chinese pill, known as VV116, recovered after a median time of 4 days and it had fewer adverse effects compared with the Pfizer drug.

videocam
4
The Chinese pill is derived from Remdesivir. Photo: Handout
Coronavirus pandemic

WHO pleased to see China ease strict zero-Covid policies

It’s important that governments listen ‘when the people are in pain,’ a top official said in wake of protests in the country over coronavirus restrictions.

videocam
Coronavirus pandemic: All stories

What’s next for pandemic winner Pfizer and its US$28 billion war chest?

Pfizer’s Covid-19 vaccine saw the pharmaceutical company become the world’s most visible drug maker, but with its stock falling in 2022, success has left investors impatient for an encore.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement